Our site uses cookies to improve the contents of the site and customize it according to individual use. Please confirm that you agree to our use of cookies by clicking Yes.

If you continue without explicit consent, we will assume that you agree to our cookie policy.

MEDISOA comprehensive portal site for
Medical Innovation Support Office (MEDISO).Medical Innovation Support Office

厚生労働省

Knowledgeable experts support the practical application of medicines, medical devices, and regenerative medicinal products.

2021.11.19【広報】経済産業省主催|ジャパン・ヘルスケアビジネスコンテスト(JHeC)2022 最終プレゼン審査 一般視聴者募集のご案内<締め切り:2022年1月12日(水)>

NEWS

経済産業省より、ジャパン・ヘルスケアビジネスコンテスト(JHeC)2022 最終プレゼン審査 一般視聴者募集についてご案内がありました。

2021.11.12JHVS2021 Global Pitch開催(Live配信)

NEWS

JHVS2021の企画として、JHVS2021 Global Pitchを「2021年11月16日(火)18:00 - 20:00」に開催します。

2021.10.21【広報】AMED_創薬支援推進事業・希少疾病用医薬品指定前実用化支援事業の公募のご案内<締め切り:11月25日(木)正午>

NEWS

国立研究開発法人日本医療研究開発機構(AMED)より創薬支援推進事業・希少疾病用医薬品指定前実用化支援事業の公募のご案内がありました。

2021.07.20MEDISOインタビュー記事 株式会社リボルナバイオサイエンス様

NEWS

MEDISO相談企業である株式会社リボルナバイオサイエンス様がBiogenと中枢神経疾患領域における医薬品の共同研究開発ならびにオプション付ライセンス契約を締結されたことを発表されました。

お知らせをもっと見る

What is MEDISO

MEDISO provides support for business ventures, academia,
and individuals intending to put into practical use medicines,
medical devices, and regenerative medicinal products.
Click here for further details.

About the Medical Innovation Support Office

The medical innovation support office matches medical venture companies and academic institutions facing challenges in the practical application of medical products and devices for specialists* who provide detailed consultation and support for solving problems at each stage from research and development to practical use, as well as insurance coverage at clinical sites, while looking ahead to the overall comprehensive advances and dissemination into the global market.
* Specialists in each field provide support for the response to laws and regulations, marketing, business planning, fund rasing, management strategy, intellectual property management, and international development, etc.

This website is operated by Mitsubishi Research Institute, Inc., as a trustee under instructions from the Economic Affairs Division, Health Policy Bureau, and Ministry of Health, Labour and Welfare as a part of the total support for the medical ventures program sponsored by the Ministry of Health, Labour and Welfare.

Support targets

Ventures, academic institutions, and individuals aiming to put into practical use the medicines, medical devices, regenerative medicinal products, and novel drug-discovery technologies or medical materials subject to the Pharmaceuticals and Medical Devices Law.

Details of support

MEDISO provides support for the practical application of medicines, medical devices, regenerative medicinal products, and other products subject to the Pharmaceuticals and Medical Devices Law.
That support includes business planning, financing, advice on laws and regulations, and other assistance as required.

Click here for inquiries and consultation requests

Specialists Introduction

We will introduce registered specialists
(updated as necessary).

Satoshi Fukushima

Globis Capital Partners & Co.

Main specialty areas

  • medical devices

Specialized support fields

  • Regulatory compliance
  • Marketing
  • Business planning
  • Funding
  • Business operation systems

He graduated from the Faculty of Economics, University of Tokyo. He was involved in investment activities in reformed fields of existing industries, including digital health, at Globis Capital Partners & Co. (GCP). He served as an outside director of several companies, including Medley, Inc., Kakehashi Inc., and Yoriso. Co. Ltd., and provided support to their management personnel mainly in strategy formulation, development of the organization, and finance. In addition to investigation activities, he provided support for fund structuring and open innovations provided by large companies in healthcare fields.

Before joining GCP, he was serving as an M&A advisor mainly in the technology, media, and telecommunication fields and worked on financing at the general headquarters of German Securities Finance Corporation.

Yoshinori Shinoki

 

Main specialty areas

  • medicines
  • medical devices
  • regenerative medicine products

Specialized support fields

  • Regulatory compliance
  • Marketing
  • Business planning
  • Business operation systems

He graduated from the Department of Biopharmaceutical Sciences, Kyoto Pharmaceutical University, and is a licensed pharmacist. At Sawai Pharmaceutical Co., Ltd., and Eli Lilly Japan K.K., after taking charge of clinical development, SOP/training, sales planning, management planning office, etc., he acquired experience in planning and implementing various clinical development plans as a project leader for newly developed items in the project management department. In addition, he was involved in formulating a drug price negotiation strategy, post-marketing clinical studies and post-marketing surveillance, and market planning. After that, he launched the clinical development department at Global CRO. Since 2015 when he took his current position, he has supported the planning of the clinical development of development items for small and biological products, as well as negotiating with regulatory authorities. Recently, in addition to medicines, he also supports clinical development strategies of medical devices and the products of regenerative medicine (gene therapy products and cell/tissue processed products) and planning.

Jun Utsumi

CEO, TIR Research Consulting, LLC. and Senior Advisor, Japanese Foundation for Cancer Research

Main specialty areas

  • medicines
  • medical devices
  • regenerative medicine products

Specialized support fields

  • Regulatory compliance
  • Marketing
  • Business planning
  • Business operation systems
  • Specialized support fields

He graduated from the Graduate School of Veterinary Medicine, Hokkaido University. He has a Doctor of Science degree and an MBA; he is a professional engineer (biotechnology), PMRJ-certified regulatory science expert, and veterinarian (DVM). He was in charge of pharmaceutical research and clinical development at Toray Industries, Inc., and successfully developed a novel antipruritus drug (received the Pharmaceutical Society of Japan Award for Drug Research and Development and the Annual Okochi Memorial Technology Prize). After the business career, he engaged in services for collaboration between industry and academia at Hokkaido University and Kyoto University (professor). Then he consecutively held positions as an expert consultant on pharmaceutical affairs strategy in the Pharmaceuticals and Medical Devices Agency (PMDA) and a senior consultant for intellectual property at the Japan Agency for Medical Research and Development (AMED). Based on more than 30 years of experience in the areas of industry, government, and academia, he established a consulting company in 2018. He is providing commercialization strategies in which the essential three factors of medical R & D—technology (T), intellectual property (I) and pharmaceutical affairs (R)—are integrated. He wrote and published “A Guide to Integrated Strategy in Drug Discovery” (Nanzando Co., 2015).

Yusuke Shinozawa

Head of the Investment and Fostering Research Center, Real Tech Fund (Leave a Nest Co., Ltd.)

Main specialty areas

  • medicines
  • medical devices
  • regenerative medicine products

Specialized support fields

  • Business planning
  • Funding
  • Business operation systems
  • Specialized support fields

He graduated with a master's degree in agriculture from the Graduate School of Agricultural and Life Sciences, University of Tokyo. After working at a PR firm, in 2009, he joined Leave a Nest Co., Ltd. In the same year, he launched a Silicon Valley training project for graduate students, which was the first overseas project for Leave a Nest Co., Ltd. In 2012, he also established a media development project, and from 2013, he established the seed acceleration project Tech Planter. He became growth manager at the Real Tech Fund in 2015, where he limited his target fields to biotechnology and marine fields, and he offered business support in these fields. In 2018, he became manager of the Frontier Development Division. He is doing his activities with “starting business operation” as his theme, not “starting a business.”

Hidehiro Ando

Representative, Andy Pharma Partners

Main specialty areas

  • medicines
  • medical devices
  • regenerative medicine products

Specialized support fields

  • Business operation systems

He graduated from the Department of Veterinary Medical Science, Faculty of Agriculture, University of Tokyo. He joined Tanabe Pharma Corporation (present Mitsubishi Tanabe Pharma Corporation). After being assigned to the research department of pharmacokinetics, he was involved in partnership-related business of international development department, research and development planning department, etc., including establishment of a joint venture with overseas companies. Subsequently, he worked in the technology transfer department of RIKEN (Institute of Physical and Chemical Research), a regenerative medicine venture, Bayer Yakuhin, a drug discovery venture, and he established a personal office. He has engaged in business development and licensing work for about 35 years, and now, based on his experience and networks, he is supporting business development activities, such as licensing agreements and joint research of domestic and foreign pharmaceutical companies/ventures. He provides comprehensive support services ranging from looking for appropriate partners, preparing the draft of contract outline, contract negotiation, and alliance management with partners after the partnership agreement. Especially, based on experience of practicing on both sides of venture and pharmaceutical companies, he keeps in mind providing informative advice and proposals for specific action plans.

About details of specialists

Introduction of measures implemented by public institutions

We will describe the measures from public institutions for pharmaceutical companies,
medical device companies, companies manufacturing regenerative medicinal products, and venture companies.

See more about measures implemented by public institutions